Navigation Links
Ohio State implants first brain pacemaker to treat Alzheimer's
Date:1/23/2013

COLUMBUS, Ohio During a five-hour surgery last October at The Ohio State University Wexner Medical Center, Kathy Sanford became the first Alzheimer's patient in the United States to have a pacemaker implanted in her brain.

She is the first of up to 10 patients who will be enrolled in an FDA-approved study at Ohio State's Wexner Medical Center to determine if using a brain pacemaker can improve cognitive and behavioral functioning in patients with Alzheimer's disease.

The study employs the use of deep brain stimulation (DBS), the same technology used to successfully treat about 100,000 patients worldwide with movement disorders such as Parkinson's disease. In the study, researchers hope to determine whether DBS surgery can improve function governed by the frontal lobe and neural networks involved in cognition and behavior by stimulating certain areas of the brain with a pacemaker.

Dr. Douglas Scharre, neurologist and director of the division of cognitive neurology, and Dr. Ali Rezai, neurosurgeon and director of the neuroscience program, both at Wexner Medical Center, are conducting the study.

"If the early findings that we're seeing continue to be robust and progressive, then I think that will be very promising and encouraging for us," says Rezai, who also directs the Center for Neuromodulation at Ohio State. "But so far we are cautiously optimistic."

The deep brain stimulation implant is similar to a cardiac pacemaker device with the exception that the pacemaker wires are implanted in the brain rather than the heart.

"Basically, the pacemakers send tiny signals into the brain that regulate the abnormal activity of the brain and normalize it more," says Rezai. "Right now, from what we're seeing in our first patient, I think the results are encouraging, but this is research. We need to do more research and understand what's going on."

The study, which will enroll people with mild or early-stage Alzheimer's disease, will help determine if DBS has the potential to improve cognitive, behavioral and functional deficits.

Sanford continues to be evaluated to determine the effectiveness of the technology, says Rezai. She says she volunteered for the study to help others avoid the angst she has suffered as Alzheimer's slowly disrupted her life.

"I'm just trying to make the world a better place," says Sanford. "That's all I'm doing."

Her father, Joe Jester, says he is proud that his daughter is participating in the study, and is pleased to see her showing improvements.

"This study seemed to just give us hope," said Jester. "I guess we were at the place where you just don't do anything and watch the condition deteriorate over the years, or try to do something that would give us hope and might stop the progression of this disease."

Alzheimer's disease is the most common form of degenerative dementia, afflicting about 5.5 million Americans and costing more than $100 billion per year, ranking it the third costliest disease in terms of health care expenditures in the United States.

Alzheimer's disease which has no cure and is not easily managed becomes progressively disabling with loss of memory, cognition, worsening behavioral function, in addition to a gradual loss of independent functioning, says Scharre.

The Ohio State neurology team is nationally renowned for expertise in dementia and Alzheimer's care and research. In addition, the neuromodulation team at Ohio State are pioneers in the use of DBS to treat Parkinson's disease, as well as exploring the use of DBS for other neurological and neurobehavioral conditions. Researchers at the Neuromodulation Center are completing a study of DBS in patients with traumatic brain injuries, and have initiated a study of DBS for treating obesity.

The Alzheimer's study is scheduled to be completed in 2015.


'/>"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-3737
MediaSource
Source:Eurekalert  

Related medicine news :

1. Study reveals how cancer drug causes diabetic-like state
2. New drug prevents spread of human prostate cancer cells
3. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
4. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
5. Study examines adverse effects among different radiation therapies for prostate cancer
6. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
7. Warren Buffett Has Early Stage Prostate Cancer
8. Majority of states fail to address youth exposure to alcohol marketing
9. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
10. PSA screening to detect prostate cancer can be beneficial to younger and at-risk men
11. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Ohio State implants first brain pacemaker to treat Alzheimer's
(Date:12/7/2016)... Hamden, CT (PRWEB) , ... December 07, 2016 , ... ... has prompted an outpouring of comments on social media that offer a rare glimpse ... adult psychiatrist, leading ADHD authority and New York Times bestselling author, has described people ...
(Date:12/7/2016)... ... 2016 , ... They are musicians and librarians, fashion designers and fitness instructors, ... New England and around the nation. What do they have in common? All have ... beautiful and compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... is now promoting to the US market its advanced highly customizable contact technology ... and ODU TURNTAC®. These advanced technologies are ideal for a wide range of ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... consultation services to residents in the Sacramento/Folsom region, is initiating a charity event ... , The Another Choice Another Chance treatment center in Sacramento works to provide ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... One ... regular changing of the securement tape is painful for her. "This is why the ... to patients’ heads," she said. , They then created a prototype of the patent-pending ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... VILLAGE, Calif. , Dec. 6, 2016 ... privately held, clinical-stage medical dermatology and aesthetics ... plc, a privately held specialty pharmaceutical company ... common inflammatory skin conditions, including psoriasis, atopic ... of the agreement, Sienna will make an ...
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, Inc. ... company, announced today that it entered into collaboration ... therapeutics for the treatment of NASH and other ... delivery platform LUNAR™ and UNA Oligomer chemistry. The ... Takeda,s long-standing commitment to and expertise in GI ...
(Date:12/6/2016)... , Dec. 6, 2016  Regulus Therapeutics Inc. ... leading the discovery and development of innovative medicines ... candidates at its R&D day, held in ... RGLS5040, is an anti-miR targeting microRNA-27 (miR-27) for ... RGLS4326, is an anti-miR targeting microRNA-17 (miR-17) for ...
Breaking Medicine Technology: